BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 38610029)

  • 21. Preclinical development of a chimeric antigen receptor T cell therapy targeting FGFR4 in rhabdomyosarcoma.
    Tian M; Wei JS; Shivaprasad N; Highfill SL; Gryder BE; Milewski D; Brown GT; Moses L; Song H; Wu JT; Azorsa P; Kumar J; Schneider D; Chou HC; Song YK; Rahmy A; Masih KE; Kim YY; Belyea B; Linardic CM; Dropulic B; Sullivan PM; Sorensen PH; Dimitrov DS; Maris JM; Mackall CL; Orentas RJ; Cheuk AT; Khan J
    Cell Rep Med; 2023 Oct; 4(10):101212. PubMed ID: 37774704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma.
    Liu X; Gao F; Jiang L; Jia M; Ao L; Lu M; Gou L; Ho M; Jia S; Chen F; Gao W
    J Transl Med; 2020 Aug; 18(1):295. PubMed ID: 32746924
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor.
    Sun S; Ding Z; Gao L; Hammock BD; Huang X; Xu ZP; Wang X; Cheng Q; Mo F; Shi W; Xie S; Liu A; Li H; Yang X; Lu X
    Theranostics; 2023; 13(14):5099-5113. PubMed ID: 37771772
    [No Abstract]   [Full Text] [Related]  

  • 24. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preparation and Characterization of Anti-GPC3 Nanobody Against Hepatocellular Carcinoma.
    Xia L; Teng Q; Chen Q; Zhang F
    Int J Nanomedicine; 2020; 15():2197-2205. PubMed ID: 32280214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma.
    Zhai Y; He K; Huang L; Shang X; Wang G; Yuan G; Han ZG
    Liver Int; 2022 Nov; 42(11):2524-2537. PubMed ID: 36002393
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma.
    Liu G; Rui W; Zheng H; Huang D; Yu F; Zhang Y; Dong J; Zhao X; Lin X
    Eur J Immunol; 2020 May; 50(5):712-724. PubMed ID: 31981231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunogenicity Risk Profile of Nanobodies.
    Ackaert C; Smiejkowska N; Xavier C; Sterckx YGJ; Denies S; Stijlemans B; Elkrim Y; Devoogdt N; Caveliers V; Lahoutte T; Muyldermans S; Breckpot K; Keyaerts M
    Front Immunol; 2021; 12():632687. PubMed ID: 33767701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BiTE-Secreting CAR-γδT as a Dual Targeting Strategy for the Treatment of Solid Tumors.
    Huang SW; Pan CM; Lin YC; Chen MC; Chen Y; Jan CI; Wu CC; Lin FY; Wang ST; Lin CY; Lin PY; Huang WH; Chiang YT; Tsai WC; Chiu YH; Lin TH; Chiu SC; Cho DY
    Adv Sci (Weinh); 2023 Jun; 10(17):e2206856. PubMed ID: 37078788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting CD38-Expressing Multiple Myeloma and Burkitt Lymphoma Cells In Vitro with Nanobody-Based Chimeric Antigen Receptors (Nb-CARs).
    Hambach J; Riecken K; Cichutek S; Schütze K; Albrecht B; Petry K; Röckendorf JL; Baum N; Kröger N; Hansen T; Schuch G; Haag F; Adam G; Fehse B; Bannas P; Koch-Nolte F
    Cells; 2020 Jan; 9(2):. PubMed ID: 32013131
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HGF-Based CAR-T Cells Target Hepatocellular Carcinoma Cells That Express High Levels of c-Met.
    Ma H; Wei W; Liang D; Xu X; Yang D; Wang Q; Wang Y; Wei Q; Sun B; Zhao X
    Immunol Invest; 2023 Nov; 52(6):735-748. PubMed ID: 37409941
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
    Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
    Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.
    Xiong Q; Wang H; Shen Q; Wang Y; Yuan X; Lin G; Jiang P
    J Transl Med; 2024 Apr; 22(1):368. PubMed ID: 38637886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma.
    Wu X; Luo H; Shi B; Di S; Sun R; Su J; Liu Y; Li H; Jiang H; Li Z
    Mol Ther; 2019 Aug; 27(8):1483-1494. PubMed ID: 31078430
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Soluble programmed death ligand-1-induced immunosuppressive effects on chimeric antigen receptor-natural killer cells targeting Glypican-3 in hepatocellular carcinoma.
    Chen L; Liu S; Adah D; Sun Q; Liang Z; Ho M; Sun B
    Immunology; 2023 Jun; 169(2):204-218. PubMed ID: 36640111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells.
    Qin A; Qin Y; Lee J; Musket A; Ying M; Krenciute G; Marincola FM; Yao ZQ; Musich PR; Xie Q
    J Transl Med; 2023 Oct; 21(1):682. PubMed ID: 37779207
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells.
    Sun B; Yang D; Dai H; Liu X; Jia R; Cui X; Li W; Cai C; Xu J; Zhao X
    Cancer Immunol Res; 2019 Nov; 7(11):1813-1823. PubMed ID: 31484657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Engineered Jurkat Cells for Targeting Prostate-Specific Membrane Antigen on Prostate Cancer Cells by Nanobody-Based Chimeric Antigen Receptor.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Abdoli S; Modarressi MH; Abolhassani M
    Iran Biomed J; 2020 Mar; 24(2):81-8. PubMed ID: 31677604
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Screening and characterization of the scFv for chimeric antigen receptor T cells targeting CEA-positive carcinoma.
    Zhang C; Wang L; Zhang Q; Shen J; Huang X; Wang M; Huang Y; Chen J; Xu Y; Zhao W; Qi Y; Li Y; Ou Y; Yang Z; Qian C
    Front Immunol; 2023; 14():1182409. PubMed ID: 37304295
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.